Table 2.
Primary and secondary outcomes
| Outcome | Oral sildenafil | Oral bosentan | p-value |
|---|---|---|---|
|
Primary outcome Hours taken for pulmonary systolic arterial pressure to reduce by 25%, Median (IQR) |
36 (24–48) | 96 (42–120) | 0.008 α |
| Secondary outcomes | |||
| Failure rate, n (%) | 3 (16.6%) | 12 (66.6%) | 0.002 β |
|
Tapering of drug n (%) Tapering possible Changed as no response Stopped due to hypotension |
16 (88.8%) 1 (5.5%) 1 (5.5%) |
8 (44.4%) 9 (50%) 1 (5.5%) |
0.011 β |
| Requirement of other pulmonary vasodilators, n (%) | 3 (16.6%) | 11 (61.1%) | 0.006 β |
|
Requirement of vasopressor agent, n (%) Noradrenaline Adrenaline |
2 (11.1%) 1 (5.5%) |
2 (11.1%) 0 |
0.99 β |
|
Hours on invasive ventilation Median (IQR) |
82 (43–98) n = 13 |
67 (30-129.5) n = 13 |
0.793 α |
| Hours on non-invasive ventilation, Median (IQR) |
90 (46–124) n = 17 |
132 (79–167) n = 18 |
0.079 α |
|
Hours taken to reach room air (FiO2 0.21 and off respiratory support) Median (IQR) |
114 (85–200) | 179 (139.5–287) | 0.077 α |
|
Days taken to achieve full feeds, Median (IQR) |
5(4.5-7) n = 16 |
6.5 (5.75–7.25) n = 18 |
0.153 α |
|
Duration of hospital stay (days), Median (IQR) |
10.5 (7.75-14) | 18 (10.75–20.25) | 0.064 α |
|
Complications n (%) Hypotension |
1(5.5%) | 1(5.5%) | > 0.99 β |
| Mortality n (%) | 1 (5.5%) | 0 | 0.310 β |
|
α Mann-Whitney U-test β Chi-Square test | |||